• Mashup Score: 0

    April 28, 2023 — Medtronic today shared additional 36-month data from the IN.PACT AV Access Study, as well as 48-month vital status outcomes. The data was presented by Professor Andrew Holden, director of interventional radiology and associate professor of radiology, Auckland University School of Medicine, as a podium first at the 2023 Charing Cross Symposium in London.  The IN.PACT AV Access…

    Tweet Tweets with this article
    • @DAICeditor @Medtronic #Medtronic shared additional 36-month data from the #IN_PACT #AV Access #Study, as well as 48-month vital status outcomes: https://t.co/LAQY2CfQvB

  • Mashup Score: 21

    Study Was Evaluating the Use of Apixaban in Patients Treated with Mechanical Aortic Valves ATLANTA, Sept. 23, 2022 /PRNewswire/ — Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it has stopped the PROACT Xa clinical trial, a prospective, randomized, trial designed to determine if patients with an On-X mechanical aortic…

    Tweet Tweets with this article
    • The #PROACT Xa trial has been halted prematurely after it was found that #Apixaban carried a greater risk of blood clots leading to stroke when compared with #warfarin in patients with the on-X mechanical #AV https://t.co/Wqbla1Hr6y @mmamas1973 @HeartOTXHeartMD @SchakrabartiEP https://t.co/a2DbWbMbYC